- Research Article
- 10.1007/s00467-026-07268-9
A pediatric case of C3 glomerulonephritis initially misclassified as IgA nephropathy with a favorable response to C3-targeted therapy.
- Mar 22, 2026
- Pediatric nephrology (Berlin, Germany)
- Laura F Alconcher + 3 more +3
C3 glomerulopathy is an ultra-rare kidney disease driven by dysregulation of the alternative complement pathway fluid phase C3 convertase. We report the case of a previously healthy 13-year-old girl who presented with concurrent nephrotic and nephritic syndrome and low complement C3. Her initial kidney biopsy surprisingly showed mesangioproliferative glomerulonephritis with dominating IgA deposits resulting in a diagnosis of IgA nephropathy. Despite standard immunosuppressive treatment with prednisone and mycophenolic acid plus angiotensin-converting enzyme inhibitors, she achieved only partial remission and subsequently relapsed, exhibiting severe, persistent C3 consumption (6-8mg/dl) and sustained C5b9 activation (1059ng/ml). A repeat biopsy 1.2years later established the definitive diagnosis of C3 glomerulonephritis (C3GN) with a membranoproliferative pattern. C3NEF antibodies were negative, and no pathological variant was detected in the genetic study. After 1year and 9months without response to immunosuppressive treatment, the C3 inhibitor pegcetacoplan was initiated. The patient achieved rapid and complete remission within 3months, marked by normalization of proteinuria, from 2747mg/day (urine protein-to-creatinine ratio [UPCR] 2.66mg/mg) pre-treatment to 19mg/d (UPCR 0.02mg/mg) and complement activation markers (from 1162ng/ml pre-treatment to C5b9 92ng/ml; reference value 30-150ng/ml). This case highlights the inherent diagnostic complexity of C3GN, suggesting the critical role of repeat biopsies in treatment-refractory, complement-dysregulated glomerulonephritis. It strongly supports the potential efficacy of C3 inhibition as a targeted therapeutic approach for patients with C3GN.
Read more